文献速递乳腺癌放疗

保乳术后接受放疗的乳腺癌患者淋巴细胞预后价值:一项III期随机试验的事后分析

Prognostic value of lymphocytes in patients with breast cancer receiving radiotherapy after breast-conserving surgery: A post hoc analysis of a phase III randomized trial.
PubMed 文献 · Radiother Oncol · 2024-06-17

该研究为一项III期随机对照试验的事后分析,纳入628例保乳术后接受大分割或常规分割放疗的乳腺癌患者。放疗期间46.1%患者出现淋巴细胞减少,多为轻度;放疗前外周淋巴细胞计数<1.77×10⁹/L与更差的10年乳腺癌特异性生存和总生存显著相关,为独立预后因素。

要点

  • 放疗期间46.1%患者出现淋巴细胞减少,3级仅2.8%,无4级。
  • 放疗前外周淋巴细胞计数<1.77×10⁹/L者10年乳腺癌特异性生存和总生存显著更低。
  • 放疗后1、3、6个月及1年淋巴细胞计数或恢复与生存无关。

核心结论

  • 保乳术后乳腺癌患者放疗所致淋巴细胞减少多较轻微,放疗前外周淋巴细胞计数较低可预测更差的生存。

研究设计与样本

  • 本研究为一项III期随机对照试验的事后分析,该试验比较保乳术后大分割放疗与常规分割放疗,共纳入628例患者。

主要发现

  • 放疗期间共275例(46.1%)患者出现淋巴细胞减少,其中17例(2.8%)为3级,无人发生4级淋巴细胞减少。
  • 中位随访110.8个月,放疗前外周淋巴细胞计数<1.77×10⁹/L的患者10年乳腺癌特异性生存率显著更低(P=0.013),10年总生存率也显著更低(P=0.026)。
  • 外周淋巴细胞计数最低值<1.35×10⁹/L的患者10年总生存率显著更差(P=0.048)。
  • 多因素分析显示,放疗前外周淋巴细胞计数<1.77×10⁹/L是影响乳腺癌特异性生存和总生存的独立因素,而最低值的影响不再显著。
  • 放疗后1、3、6个月及1年时的外周淋巴细胞计数或淋巴细胞减少恢复情况均与生存无关。

关键数值与推荐

  • 放疗前外周淋巴细胞计数<1.77×10⁹/L者10年乳腺癌特异性生存率显著更低(P=0.013),10年总生存率显著更低(P=0.026)。
  • 外周淋巴细胞计数最低值<1.35×10⁹/L者10年总生存率显著更差(P=0.048)。
  • 放疗期间3级淋巴细胞减少发生率为2.8%(17/628),无4级淋巴细胞减少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the prognostic value of peripheral lymphocyte count (PLC) in the breast cancer patients after breast-conserving surgery (BCS) with radiotherapy (RT). METHODS AND MATERIALS: This post hoc analysis was performed using data of 628 patients from a phase III, randomized controlled trial comparing hypofractionated RT (HFRT) with conventional fractionated RT (CFRT) after BCS. PLCs were obtained before, during, and after RT until the 1-year follow-up. The optimal cut-off PLCs were determined using the maxstat package in R. Survival rates were estimated using the Kaplan-Meier method and compared with the log-rank test. RESULTS: A total of 275 (46.1 %) patients developed lymphopenia during RT, among them, 17 (2.8 %) had grade 3 lymphopenia and no one developed grade 4 lymphopenia. With a median follow-up of 110.8 months, patients with pre-RT PLCs of < 1.77 × 109/L had a significantly lower 10-year breast cancer-specific survival (BCSS) rate (P = 0.013) and overall survival (OS) rate (P = 0.026). Patients with a nadir PLC of < 1.35 × 109/L had a significantly poorer 10-year OS rate (P = 0.048). Multivariate analysis showed that a pre-RT PLC of < 1.77 × 109/L was an independent factor influencing BCSS and OS, while the effect of the nadir PLC did not remain significant. Neither PLC nor lymphopenia recovery at post-RT 1, 3, and 6 months and 1 year was associated with survival. CONCLUSIONS: Radiation-induced lymphopenia in patients with breast cancer after BCS tends to be mild. The lower pre-RT PLC predicted poorer survival.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Song YC, Chen SY, Zhao XR, et al. Prognostic value of lymphocytes in patients with breast cancer receiving radiotherapy after breast-conserving surgery: A post hoc analysis of a phase III randomized trial. Radiother Oncol. 2024. PMID: 38897316. doi:10.1016/j.radonc.2024.110390

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。